Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4

Biochemical Pharmacology

Volumn 53, Issue 4, 1997, Pages 455-460

  Koley, Aditya P ^a   Robinson, Richard C ^a   Markowitz, Allen ^b   Friedman, Fred K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

cytochrome P450; drug interactions; nifedipine; quinidine

Indexed keywords

CARBON MONOXIDE; CYTOCHROME P450 ISOENZYME; NIFEDIPINE; QUINIDINE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

EID: 0031581857     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00836-2     Document Type: Article

References (18)

1. 1. Stockley IH, Drug Interactions: A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management. Blackwell Scientific Publications, Oxford, 1994.
2. 2. D'Arcy PF, McElnay JC and Welling PG, Mechanisms of Drug Interactions. Springer, Berlin, 1996.
3. 3. Schellens JH, Ghabrial H, van der Wart HH, Bakker EN, Wilkinson GR and Breimer DD, Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 50: 520-528, 1991.
4. 4. Bowles SK, Reeves RA, Cardozo L and Edwards DJ, Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. J Clin Pharmacol 33: 727-731, 1993.
5. 5. Bailey DG, Freeman DJ, Melendez LJ, Kreeft JH, Edgar B and Carruthers SG, Quinidine interaction with nifedipine and felodipine: Pharmacokinetic and pharmacodynamic evaluation. Clin Pharmacol Ther 53: 354-359, 1993.
6. 6. Hippius M, Henschel L, Sigusch H, Tepper J, Brendel E and Hoffmann A, Pharmacokinetic interactions of nifedipine and quinidine. Pharmazie 50: 613-616, 1995.
7. 7. Wrighton SA and Stevens JC, The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22: 1-21, 1992.
8. 8. Li AP, Kaminski DL and Rasmussen A, Substrates of human hepatic cytochrome P450 3A4. Toxicology 104: 1-8, 1995.
9. 9. Hiller A, Olkkola KT, Isohanni P and Saarnivaara L, Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 65: 826-828, 1990.
10. 10. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269: 1513-1518, 1993.
11. 11. Kivisto KT, Neuvonen PJ and Klotz U, Inhibition of terfenadine metabolism: Pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 27: 1-5, 1994.
12. 12. Koley AP, Robinson RC and Friedman FK, Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. Biochimie 78: 706-713, 1996.
13. 13. Buters JTM, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP and Gonzalez FJ, cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 22: 688-692, 1994.
14. 14. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2385, 1964.
15. 15. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC, Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
16. 16. Koley AP, Robinson RC, Markowitz A and Friedman FK, Kinetics of CO binding to cytochrome P450 in the endoplasmic reticulum. Biochemistry 33: 2484-2489, 1994.
17. 17. Koley AP, Buters JTM, Robinson RC, Markowitz A and Friedman FK, CO binding kinetics of human cytochrome P450 3A4: Specific interaction of substrates with kinetically distinguishable conformers. J Biol Chem 270: 5014-5018, 1995.
18. 18. Bruns RF, Conformational induction versus conformational selection: Evidence from allosteric enhancers. Trends Pharmacol Sci 17: 189, 1996.